Recombinant Rat B7-H4 protein (rFc Tag)

Species

Rat

Purity

>90 %, SDS-PAGE

Tag

rFc Tag

Activity

not tested

Cat no : Eg3230

---

Validation Data Gallery

• 

  Purity of Recombinant Rat B7-H4 was determined by SDS-PAGE. The protein was resolved in an SDS-PAGE in reducing (R) and non-reducing (NR) conditions and stained using Coomassie blue.

---

Product Information

• Purity: >90 %, SDS-PAGE
• Endotoxin: <0.1 EU/μg protein, LAL method
• Activity:

  Not tested

• Expression: HEK293-derived Rat B7-H4 protein Phe29-Gly257 (Accession# Q501W4) with a rabbit IgG Fc tag at the C-terminus.
• GeneID: 295322
• Accession: Q501W4
• PredictedSize: 51.5 kDa
• SDS-PAGE: 65-90 kDa, reducing (R) conditions
• Formulation: Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.
• Reconstitution: Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.
• Storage Conditions:
  It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
  • Until expiry date, -20℃ to -80℃ as lyophilized proteins.
  • 3 months, -20℃ to -80℃ under sterile conditions after reconstitution.
• Shipping: The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

Background

B7-H4, also known as V-set domain containing T cell activation inhibitor 1 (VTCN1/B7x/B7 homolog4/B7S1), belongs to the coinhibitory B7 family ligands. B7-H4 is a type I transmembrane protein and is thought to be an immune checkpoint molecule in the context of tumor immunity. B7-H4 is nominally expressed in normal tissues yet is highly expressed in many types of cancer, including breast cancer, cholangiocarcinoma, endometrial carcinoma, non-small cell and squamous cell lung carcinoma, and ovarian carcinoma. High B7-H4 expression often correlates with shorter cancer patient survival.

References:

1.Song X, et al. (2020) Cancer Discov. 10(12):1872-1893.
2.Kinneer K, et al. (2023) Clin Cancer Res. 29(6):1086-1101.
3.Toader D, et al. (2023) Mol Cancer Ther. 22(9):999-1012.
4.Yu J, et al. (2024) Cell. 187(17):4713-4732.e19.